Because both Opdivo and Keytruda are anti-PD-1 agents, the FDA took a cautious approach. So why not sell Bristol-Myers Squibb stock? There's a good chance that Opdivo will succeed more than it fails in the remaining clinical …
Bristol-Myers Squibb's stock fell nearly 10 percent yesterday after the company released a disappointing earnings forecast. The news helped send the prices of other drug stocks tumbling. . The shares of the Bristol-Myers Squibb …
Bristol Myers Squibb Co. (NYSE:BMY) is down 5% so far this year, as the company saw bad news break in early August when it suspended a trial for its prospective drug for treating hepatitis C following safety concerns. This followed Bristol
Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment …
Key highlights in the pharma sector include a complete response letter (“CRL”) from the FDA for Johnson & Johnson’s JNJ investigational rheumatoid arthritis (“RA”) treatment and FDA approval for Merck’s MRK and Bristol-Myers Squibb’s …
Bristol-Myers Co. disclosed plans Thursday to acquire Squibb Corp. in a stock transaction currently valued at about $11.5 billion. If completed, the giant deal would continue the consolidation in the worldwide pharmaceutical industry. It also …
Bristol-Myers Squibb Company (NYSE: BMY) and Mead Johnson Nutrition Company (NYSE: MJN) announced today …
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three clinical trials for Opdivo in combination …